These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37384899)

  • 41. The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina.
    Banegas RA; Farache F; Rancati A; Chain M; Gallagher CJ; Chapman MA; Caulkins CA
    Aesthet Surg J; 2013 Sep; 33(7):1039-45. PubMed ID: 23990584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines.
    Dayan S; Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Munavalli G; Prygova I
    J Cosmet Dermatol; 2022 Jun; 21(6):2407-2416. PubMed ID: 35266281
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids.
    Beer KR
    Dermatol Surg; 2006 Feb; 32(2):184-97. PubMed ID: 16442037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel Device Made from a Surgical Mask to Enhance the Safety of Botulinum Toxin and Filler Injections for Glabellar Lines.
    Hung YT; Cheng CY; Huang YL
    Plast Reconstr Surg; 2023 Mar; 151(3):533e-534e. PubMed ID: 36730141
    [No Abstract]   [Full Text] [Related]  

  • 45. Evaluation of the safety and efficacy of a biosimilar abobotulinum toxin type A in treating moderate-to-severe glabellar lines: A non-inferiority double blinded randomized controlled trial.
    Afshani SM; Samadi A; Ayatollahi A; Kashani MN; Ahmad Nasdrollahi S; Hosseini H; Rezagholi Z; Hedayatjoo B; Hazegh Fetratjoo D; Ghobadi MA; Anari A; Saeedifar S; Firooz A
    J Cosmet Dermatol; 2022 Jun; 21(6):2398-2406. PubMed ID: 35340107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. OnabotulinumtoxinA treatment of mild glabellar lines in repose.
    Carruthers A; Carruthers J; Lei X; Pogoda JM; Eadie N; Brin MF
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2168-71. PubMed ID: 21134048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.
    Schlessinger J; Monheit G; Kane MA; Mendelsohn N
    Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines.
    Kerscher M; Fabi S; Fischer T; Gold M; Joseph J; Prager W; Rzany B; Yoelin S; Roll S; Klein G; Maas C
    J Drugs Dermatol; 2020 Oct; 19(10):985-991. PubMed ID: 33026771
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.
    Carruthers A; Carruthers J; Said S
    Dermatol Surg; 2005 Apr; 31(4):414-22; discussion 422. PubMed ID: 15871316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Kaufman-Janette J; Avelar RL; Biesman BS; Draelos ZD; Gross JE; Jones DH; Lupo MP; Maas CS; Schlessinger J; Shamban AT; Sundaram H; Weinkle SH; Young VL
    Aesthet Surg J; 2021 Nov; 41(12):1409-1422. PubMed ID: 33944905
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
    Kim JE; Song EJ; Choi GS; Lew BL; Sim WY; Kang H
    Plast Reconstr Surg; 2015 Mar; 135(3):732-741. PubMed ID: 25719692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines.
    De Boulle K; Werschler WP; Gold MH; Bruce S; Sattler G; Ogilvie P; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
    Dermatol Surg; 2018 Nov; 44(11):1437-1448. PubMed ID: 30096106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.
    Moy R; Maas C; Monheit G; Huber MB;
    Arch Facial Plast Surg; 2009; 11(2):77-83. PubMed ID: 19289677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PrabotulinumtoxinA for Treatment of Millennials With Moderate to Severe Glabellar Lines: Post Hoc Analyses of the Phase III Clinical Study Data.
    Ogilvie P; Jones DH; Avelar RL; Jonker A; Monroe R; Carruthers J
    Dermatol Surg; 2022 Jun; 48(6):664-669. PubMed ID: 35616616
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment.
    Carruthers A; Sadick N; Brandt F; Trindade de Almeida AR; Fagien S; Goodman GJ; Raspaldo H; Smith K; Darmody S; Gallagher CJ; Street J; Romagnano L
    Dermatol Surg; 2015 Jun; 41(6):693-701. PubMed ID: 25973559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimizing Outcomes When Treating Glabellar Lines.
    Solish N; Bertucci V; Green JB; Kane MAC
    Aesthet Surg J; 2023 Jun; 43(7):786-788. PubMed ID: 37217827
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
    Solish N; Rivers JK; Humphrey S; Muhn C; Somogyi C; Lei X; Bhogal M; Caulkins C
    Dermatol Surg; 2016 Mar; 42(3):410-9. PubMed ID: 26863598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impact.
    Carruthers J; Carruthers A; Blitzer A; Eadie N; Brin MF
    Medicine (Baltimore); 2023 Jul; 102(S1):e32375. PubMed ID: 37499082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study.
    Kane MAC; Brandt F; Rohrich RJ; Narins RS; Monheit GD; Huber MB;
    Plast Reconstr Surg; 2009 Nov; 124(5):1619-1629. PubMed ID: 19584772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.